Rifampicin as monotherapy for infections caused by S. aureus: Considerations for not applying “breakpoints in brackets”

Boyd, Sara E., Wootton, Mandy, Howe, Robin A., Livermore, David M., MacGowan, Alasdair P. and Kahlmeter, Gunnar and on behalf of BSAC Standing Committee on Antimicrobial Susceptibility Testing (2025) Rifampicin as monotherapy for infections caused by S. aureus: Considerations for not applying “breakpoints in brackets”. Journal of Antimicrobial Chemotherapy. ISSN 0305-7453 (In Press)

Full text not available from this repository. (Request a copy)

Abstract

EUCAST introduced “breakpoints in brackets” to warn against use of specified agents without additional therapeutic measures. Rifampicin is rarely used as monotherapy for Staphylococcus aureus infections, yet its breakpoints remain unbracketed. Here, we explore whether this remains appropriate. Although frequent emergent resistance largely precludes rifampicin’s use as monotherapy, this does not meet EUCAST’s core criterion for bracketing – that an agent is inherently ineffective as monotherapy.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Depositing User:	LivePure Connector
Date Deposited:	10 Oct 2025 11:32
Last Modified:	10 Oct 2025 11:32
URI:	https://ueaeprints.uea.ac.uk/id/eprint/100682
DOI:	issn:0305-7453

Actions (login required)

View Item